Bartlett & Co. LLC lifted its position in Eli Lilly And Co (NYSE:LLY) by 122.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,013 shares of the company’s stock after purchasing an additional 11,010 shares during the quarter. Bartlett & Co. LLC’s holdings in Eli Lilly And Co were worth $2,238,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of LLY. Nuveen Asset Management LLC raised its stake in shares of Eli Lilly And Co by 20,030.9% in the second quarter. Nuveen Asset Management LLC now owns 7,265,844 shares of the company’s stock valued at $804,983,000 after purchasing an additional 7,229,751 shares in the last quarter. Renaissance Technologies LLC raised its stake in Eli Lilly And Co by 218.6% during the second quarter. Renaissance Technologies LLC now owns 2,308,601 shares of the company’s stock worth $255,770,000 after acquiring an additional 1,583,947 shares in the last quarter. Grantham Mayo Van Otterloo & Co. LLC raised its stake in Eli Lilly And Co by 5,612.3% during the second quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,591,396 shares of the company’s stock worth $176,311,000 after acquiring an additional 1,563,537 shares in the last quarter. AQR Capital Management LLC raised its stake in Eli Lilly And Co by 53.3% during the second quarter. AQR Capital Management LLC now owns 4,335,702 shares of the company’s stock worth $480,048,000 after acquiring an additional 1,507,050 shares in the last quarter. Finally, BlackRock Inc. raised its stake in Eli Lilly And Co by 1.5% during the second quarter. BlackRock Inc. now owns 61,979,145 shares of the company’s stock worth $6,866,670,000 after acquiring an additional 898,845 shares in the last quarter. Institutional investors and hedge funds own 77.22% of the company’s stock.
Several research analysts have issued reports on LLY shares. UBS Group dropped their price objective on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research note on Thursday, October 17th. Bank of America started coverage on Eli Lilly And Co in a research note on Wednesday, October 16th. They set a “buy” rating and a $133.00 price objective for the company. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $130.03.
In related news, major shareholder Lilly Endowment Inc sold 173,918 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $114.05, for a total value of $19,835,347.90. Following the transaction, the insider now owns 116,229,383 shares in the company, valued at $13,255,961,131.15. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total value of $2,201,745.00. Following the completion of the transaction, the senior vice president now owns 38,306 shares in the company, valued at approximately $4,325,130.46. The disclosure for this sale can be found here. In the last quarter, insiders purchased 8,405 shares of company stock worth $909,004 and sold 614,373 shares worth $70,546,895. 0.11% of the stock is owned by company insiders.
Eli Lilly And Co stock traded up $0.70 during mid-day trading on Friday, hitting $113.48. 1,360,534 shares of the company were exchanged, compared to its average volume of 3,305,375. Eli Lilly And Co has a 1-year low of $101.36 and a 1-year high of $132.13. The company has a market capitalization of $106.81 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 1.82 and a beta of 0.16. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 4.09. The business has a fifty day moving average of $110.64 and a 200 day moving average of $112.68.
Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Wednesday, October 23rd. The company reported $1.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.43 by $0.05. Eli Lilly And Co had a return on equity of 107.99% and a net margin of 35.10%. The company had revenue of $5.48 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same period last year, the company posted $1.39 earnings per share. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. Research analysts expect that Eli Lilly And Co will post 5.78 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $0.645 dividend. This represents a $2.58 annualized dividend and a yield of 2.27%. The ex-dividend date is Thursday, November 14th. Eli Lilly And Co’s dividend payout ratio is 46.49%.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Why do companies engage in swaps?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.